A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Biotechnology Computer Science Energy Engineering Environmental Sciences Information Science Life Sciences Mathematics Medical Sciences

Military Sciences Natural Sciences Physical Sciences Plant Sciences Science Space Sciences Technology Transportation